MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1

Zhou, Yan; Ding, Bao-Zhong; Lin, Yunpeng; Wang, Haibo

doi:10.1016/j.gene.2017.10.046

Cited by 55 publications

(38 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, among these studies, two opposing views were presented on whether patients could bene t from the high expression of miR-34a. Hao Wu et al [7], Milad Asadi et al [47] and Yan Zhou et al [48] showed the down-regulation of miR-34a was linked to a poor prognosis in GICs patients, while Hiyoshi Y et al [8], and Mojin Wang [26] reported patients were bene ted from down-regulated miR-34a. The prognostic value of miR-34a in GICs has been illustrated in lots of studies, but the particular prognosis role of miR-34a in GICs remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis

Chen¹,

Liu²,

L³

2020

Preprint

View full text Add to dashboard Cite

Background: Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs). Methods: All the eligible studies were searched by PubMed, Web of Science and EMBASE and survival results were extracted. Then, the hazard ratio (HR) with corresponding 95% confidence intervals (CIs) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratio (OR) and 95%CIs. Results: A total of 20 studies were included in this meta-analysis. For overall survival (OS), the lower miR-34a expression significantly predicted poorer outcome in GICs, with the pooled HR of 1.86 (95% CI: 1.52-2.28, P<0.01). For disease-free survival (DFS), progressive-free survival (PFS), and recurrence-free survival (RFS), the lower miR-34a expression revealed worse DFS/PFS/RFS with the pooled HR of 1.86 (95% CI: 1.31–2.63, P < 0.01). Significant relation of differentiation/TMN stage/lymphatic metastasis and the expression level of miR-34a was identified. Conclusion: This meta-analysis reveals that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS of GICs patients. In addition, miR-34a expression level is relatively lower in patients with lymph node metastasis than patients without, and decreased miR-34a expression level is linked to poor tumor differentiation and late TMN stage. MiR-34a may become a new factor for prognosis prediction and progression of GICs.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis

Chen¹,

Liu²,

L³

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Meanwhile, several studies also confirmed that miR-34a was down-regulated in GC tissues, and was associated with tumor size, cell differentiation, distant metastasis, lymph node metastasis, recurrence and tumor lymph node metastasis (TNM) staging in patients with GC. 51,52 Additionally, the results obtained from the Cancer Genome Atlas (TCGA) database demonstrated that low-expression of miR-34a was correlated with worse clinical outcome in GC patients. 53 These findings indicate a positive relationship between abnormal expression of miR-34a and the development of GC.…”

Section: Mir-34a Expression In Gcmentioning

confidence: 99%

“…Moreover, miR-34a enhanced the sensitivity of GC cells to luteolin by directly targeting hexokinase 1 (HK1). 52 Luteolin exerts anti-tumor effects by inhibiting cell proliferation, promoting apoptosis, and inhibiting cancer cell metastasis and angiogenesis. 77,78 miR-34a was down-regulated in luteolin-resistant GC cells.…”

Section: The Role Of Mir-34a In the Treatment And Chemoresistance Of Gcmentioning

confidence: 99%

<p>A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer</p>

Kong¹,

Wang²

2020

OTT

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of endogenous non-coding single-stranded small-molecule RNAs that regulate gene expression by repressing target messenger RNA (mRNA) translation or degrading mRNA. miR-34a is one of the most important miRNAs participating in various physiological and pathological processes. miR-34a is abnormally expressed in a variety of tumors. The roles of miR-34a in gastrointestinal cancer (GIC) draw lots of attention. Numerous studies have demonstrated that dysregulated miR-34a is closely related to the proliferation, differentiation, migration, and invasion of tumor cells, as well as the diagnosis, prognosis, treatment, and chemo-resistance of tumors. Thus, we systematically reviewed the abnormal expression and regulatory roles of miR-34a in GICs including esophageal cancer (EC), gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer (PC), and gallbladder cancer (GBC). It may provide a profile of versatile roles of miR-34a in GICs.

show abstract

“…Some miRNAs, such as miR-4670-5p, miR-940, miR-493, miR-30e, and miR-7, have been shown to have antitumor effects both in vitro and in vivo, [99][100][101][102] and other miRNAs, such as miR-494, miR-124, miR-34a, miR-21, and miR-9, have been investigated in more than one study. [97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114]…”

Section: Microrna-based Other Therapiesmentioning

confidence: 99%

<p>Research Progress in microRNA-Based Therapy for Gastric Cancer</p>

Zhao

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic therapy is still an urgent problem to overcome. In the past decade, the essential roles of microRNAs (miRNAs) in tumor treatment have been increasingly recognized. In particular, miRNAs were recently shown to reverse the resistance to chemotherapy drugs such as 5-fluorouracil, cisplatin, and doxorubicin. Synthesized nanoparticles loaded with mimics or inhibitors of miRNAs can directly target tumor cells to suppress their growth. Moreover, exosomes may serve as promising safe carriers for mimics or inhibitors of miRNAs to treat GC. Some miRNAs have also been shown to play roles in the mechanism of action of other anti-tumor drugs. Therefore, in this review, we highlight the research progress on microRNA-based therapy in GC and discuss the challenges and prospects associated with this strategy. We believe that microRNA-based therapy has the potential to offer a clinical benefit to GC patients, and this review would contribute to and motivate further research to promote this field toward this ultimate goal.

show abstract

MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1

Cited by 55 publications

References 30 publications

Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis

Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis

<p>A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer</p>

<p>Research Progress in microRNA-Based Therapy for Gastric Cancer</p>

Contact Info

Product

Resources

About